Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland

British Journal of Ophthalmology

Volumn 95, Issue 11, 2011, Pages 1483-1489

  Le Tourneau, Christophe ^a   Razak, Albiruni R A ^b   Levy, Christine ^a   Calugaru, Valentin ^a   Galatoire, Olivier ^c   Dendale, Rémi ^a   Desjardins, Laurence ^a   Gan, Hui K ^d  

^a INSTITUT CURIE   (France)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^d Austin Ludwig Medical Oncology Department   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AG 013735; ANTHRACYCLINE DERIVATIVE; BATIMASTAT; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CS 055; CYCLOPHOSPHAMIDE; DASATINIB; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEFITINIB; GELATINASE B; GEMCITABINE; HBI 8000; IMATINIB; LAPATINIB; MITOXANTRONE; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN;

ADENOID CYSTIC CARCINOMA; ALOPECIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; EXTRACELLULAR MATRIX; HUMAN; KIDNEY DYSFUNCTION; LACRIMAL GLAND DISEASE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; OTOTOXICITY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SALIVARY GLAND CARCINOMA; SEPSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THROMBOSIS; VASCULAR DISEASE; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, ADENOID CYSTIC; CHEMOTHERAPY, ADJUVANT; EYE NEOPLASMS; HUMANS; LACRIMAL APPARATUS DISEASES; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS;

EID: 80054924926     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.192351     Document Type: Review

References (105)

1. Wright JE, Rose GE, Garner A. Primary malignant neoplasms of the lacrimal gland. Br J Ophthalmol 1992;76:401-7.
2. Shields JA, Shields CL, Scartozzi R. Survey of 1264 patients with orbital tumors and simulating lesions: The 2002 Montgomery Lecture, part 1. Ophthalmology 2004;111:997-1008. (Pubitemid 38586697)
3. Heeghardt S. The Annual EVER Symposium. Creta, 2010.
4. Ghabach B, Anderson WF, Curtis RE, et al. Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study. Breast Cancer Res 2010;12:R54.
5. Polito E, Leccisotti A. Epithelial malignancies of the lacrimal gland: survival rates after extensive and conservative therapy. Ann Ophthalmol 1993;25:422-6.
6. Esmaeli B, Ahmadi MA, Youssef A, et al. Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg 2004;20:22-6. (Pubitemid 38120800)
7. Triantafillidou K, Dimitrakopoulos J, Iordanidis F, et al. Management of adenoid cystic carcinoma of minor salivary glands. J Oral Maxillofac Surg 2006;64:1114-20. (Pubitemid 43867107)
8. Gurney TA, Eisele DW, Weinberg V, et al. Adenoid cystic carcinoma of the major salivary glands treated with surgery and radiation. Laryngoscope 2005;115:1278-82. (Pubitemid 40962370)
9. Hemprich A, Schmidseder R. The adenoid cystic carcinoma. Special aspects of its growth and therapy. J Craniomaxillofac Surg 1988;16:136-9.
10. Garden AS, Weber RS, Morrison WH, et al. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys 1995;32:619-26.
11. Ahmad SM, Esmaeli B, Williams M, et al. American Joint Committee on Cancer classification predicts outcome of patients with lacrimal gland adenoid cystic carcinoma. Ophthalmology 2009;116:1210-15.
12. Gamel JW, Font RL. Adenoid cystic carcinoma of the lacrimal gland: the clinical significance of a basaloid histologic pattern. Hum Pathol 1982;13:219-25. (Pubitemid 12146978)
13. Perez DE, Pires FR, Almeida OP, et al. Epithelial lacrimal gland tumors: a clinicopathological study of 18 cases. Otolaryngol Head Neck Surg 2006;134:321-5. (Pubitemid 43187135)
14. Paulino AF, Huvos AG. Epithelial tumors of the lacrimal glands: a clinicopathologic study. Ann Diagn Pathol 1999;3:199-204.
15. Ohnishi Y, Abe M, Shimokawa S, et al. Adenoid cystic carcinoma of lacrimal gland. Jpn J Ophthalmol 1983;27:96-101. (Pubitemid 13118594)
16. Tse DT, Benedetto P, Dubovy S, et al. Clinical analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. Am J Ophthalmol 2006;141:44-53.
17. Tse DT. Clinical and microdissection genotyping analyses of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. Trans Am Ophthalmol Soc 2005;103:337-67. (Pubitemid 43042099)
18. Meldrum ML, Tse DT, Benedetto P. Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland. Arch Ophthalmol 1998;116:315-21. (Pubitemid 28124397)
19. Meel R, Pushker N, Bakhshi S. Adjuvant chemotherapy in lacrimal gland adenoid cystic carcinoma. Pediatr Blood Cancer 2009;53:1163-4.
20. Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14.
21. Licitra L, Marchini S, Spinazze S, et al. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer 1991;68:1874-7.
22. Vermorken JB, Verweij J, de Mulder PH, et al. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1993;4:785-8. (Pubitemid 23340091)
23. Verweij J, de Mulder PH, de Graeff A, et al. Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1996;7:867-9. (Pubitemid 26345882)
24. Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 2001;91:541-7. (Pubitemid 32105699)
25. Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head & Neck 2006;28:197-204. (Pubitemid 43269885)
26. van Herpen CML, Locati LD, Buter J, et al. Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). Eur J Cancer 2008;44:2542-5.
27. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006;24:2673-8. (Pubitemid 46622089)
28. Airoldi M, Fornari G, Pedani F, et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res 2000;20:3781-3. (Pubitemid 32002275)
29. Laurie SA, Siu LL, Winquist E, et al. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer 2010;116:362-8.
30. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41:1751-7. (Pubitemid 41132637)
31. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34. (Pubitemid 39296599)
32. Venook AP, Blanke CD, Niedzwiecki D, et al. Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. Clin Colorectal Cancer 2005;5:292-4.
33. Sandler A, Gray R, Perry MC, et al. Paclitaxele-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. (Pubitemid 44917502)
34. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
35. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. (Pubitemid 38702844)
36. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11. (Pubitemid 350296300)
37. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-32. (Pubitemid 351264358)
38. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005;23:585-90. (Pubitemid 46224236)
39. Pfeffer MR, Talmi Y, Catane R, et al. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 2007;43:33-6. (Pubitemid 46162246)
40. Glisson B, Blumenschein G, Francisco M. Phase II trial of gefitinib in patients with incurable salivary gland cancer [abstract]. J Clin Oncol 2005;23:5532.
41. Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol 2009;45:574-8.
42. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003;39:724-7. (Pubitemid 36930120)
43. Agulnik M, Cohen EWE, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007;25:3978-84. (Pubitemid 47477277)
44. Hotte S, Chen E, Hirte H. Phase II study of sunitinib in patients (pts) with progressive metastatic adenoid cystic carcinoma (ACC) [abstract]. Eur J Cancer Suppl 2008;6:206.
45. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23:5474-83.
46. Argiris A, Goldwasser M, Burtness B. A phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: An Eastern Cooperative Oncology Group study [abstract]. J Clin Oncol 2006;24:5573.
47. Dong M, Ning Z, Newman M. Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas [abstract]. J Clin Oncol 2009;27:3529.
48. Maruyama S, Cheng J, Yamazaki M, et al. Metastasis-associated genes in oral squamous cell carcinoma and salivary adenoid cystic carcinoma: a differential DNA chip analysis between metastatic and nonmetastatic cell systems. Cancer Genet Cytogenet 2010;196:14-22.
49. Franchi A, Gallo O, Bocciolini C, et al. Reduced E-cadherin expression correlates with unfavorable prognosis in adenoid cystic carcinoma of salivary glands of the oral cavity. Am J Clin Pathol 1999;111:43-50. (Pubitemid 29024965)
50. Zhang C-Y, Mao L, Li L, et al. Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma. Cancer 2007;110:87-95. (Pubitemid 46992031)
51. Xue F, Zhang Y, Liu F, et al. Expression of IgSF in salivary adenoid cystic carcinoma and its relationship with invasion and metastasis. J Oral Pathol Med 2005;34:295-7. (Pubitemid 40524970)
52. Shirasuna K, Saka M, Hayashido Y, et al. Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation. Cancer Res 1993;53:147-52. (Pubitemid 23019390)
53. Shintani S, Alcalde RE, Matsumura T, et al. Extracellular matrices expression in invasion area of adenoid cystic carcinoma of salivary glands. Cancer Lett 1997;116:9-14. (Pubitemid 27226143)
54. Mao L, Yu S, Sun K. [An experimental study of matrix metalloproteinase inhibitor BB-94 inhibits the invasion and metastasis of the human salivary adenoid cystic carcinoma in vitro and in vivo]. Chung-Hua Kou Chiang i Hsueh Tsa Chih 2001;36:304-7.
55. Lourenco SV, Kapas S, Williams DM, et al. Expression patterns of integrins on pleomorphic adenoma and adenoid cystic carcinoma: study on specimens and in vitro investigation of the effects of extracellular matrix on the expression of these adhesion molecules. J Oral Pathol Med 2004;33:574-80. (Pubitemid 39318469)
56. Freitas VM, Vilas-Boas VF, Pimenta DC, et al. SIKVAV, a laminin alpha1-derived peptide, interacts with integrins and increases protease activity of a human salivary gland adenoid cystic carcinoma cell line through the ERK 1/2 signaling pathway. Am J Pathol 2007;171:124-38. (Pubitemid 47339233)
57. Zhang J, Peng B, Chen X. Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res 2005;11:7334-43. (Pubitemid 41507692)
58. Zhang J, Peng B. In vitro angiogenesis and expression of nuclear factor kappaB and VEGF in high and low metastasis cell lines of salivary gland adenoid cystic carcinoma. BMC Cancer 2007;7:95.
59. Yu F, Jiang Xz, Chen Wt, et al. [Microvessel density and expression of vascular endothelial growth factor in adenoid cystic carcinoma of salivary gland]. Shanghai Kou Qiang Yi Xue/Shanghai 2003;12:443-6.
60. Ishibashi H, Shiratuchi T, Nakagawa K, et al. Hypoxia-induced angiogenesis of cultured human salivary gland carcinoma cells enhances vascular endothelial growth factor production and basic fibroblast growth factor release. Oral Oncol 2001;37:77-83.
61. Liao Y, Zeng H, Wang X, et al. Expression patterns and prognostic significance of inhibitor of apoptosis proteins in adenoid cystic carcinoma and pleomorphic adenoma of lachrymal gland. Exp Eye Res 2009;88:4-11.
62. Jia L, Esguerra RL, Tang X, et al. Prognostic value of apoptosis and apoptosis-associated proteins in salivary gland adenoid cystic carcinoma. Pathol Int 2004;54:217-23. (Pubitemid 38669975)
63. Strianese D, Baldi G, Staibano S, et al. Expression of apoptosis-related markers in malignant epithelial tumours of the lacrimal gland and their relation to clinical outcome. Br J Ophthalmol 2007;91:1239-43. (Pubitemid 47344907)
64. Carlinfante G, Lazzaretti M, Ferrari S, et al. P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up. Pathol Res Pract 2005;200:791-9. (Pubitemid 40220961)
65. Ettl T, Schwarz S, Kleinsasser N, et al. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 2008;53:567-77.
66. Norberg-Spaak L, Dardick I, Ledin T. Adenoid cystic carcinoma: use of cell proliferation, BCL-2 expression, histologic grade, and clinical stage as predictors of clinical outcome. Head and Neck 2000;22:489-97. (Pubitemid 30483058)
67. Yasumatsu R, Kuratomi Y, Nakashima T, et al. Cyclin D1 expression does not effect cell proliferation in adenoid cystic carcinoma of the salivary gland. Eur Arch Oto-Rhino-Laryngol 2004;261:526-30.
68. Takata T, Kudo Y, Zhao M, et al. Reduced expression of p27(Kip1) protein in relation to salivary adenoid cystic carcinoma metastasis. Cancer 1999;86:928-35. (Pubitemid 29439845)
69. Hu K, Gan Y-H, Li S-L, et al. Relationship of activated extracellular signal-regulated kinase 1/2 with lung metastasis in salivary adenoid cystic carcinoma. Oncol Rep 2009;21:137-43.
70. Hu J-a, Li Y, Fang J, et al. Effect of ERK inhibitor on pulmonary metastasis of inoculated human adenoid cystic carcinoma cells in nude mice. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109:117-23.
71. Sun ZJ, Chen G, Hu X, et al. Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin. Apoptosis 2010;15:850-63.
72. Hara S, Nakashiro K-I, Goda H, et al. Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. Biochem Biophys Res Commun 2008;370:123-8.
73. Frierson HF Jr, El-Naggar AK, Welsh JB, et al. Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol 2002;161:1315-23.
74. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008;53:245-66.
75. Aslan DL, Oprea GM, Jagush SM, et al. c-kit expression in adenoid cystic carcinoma does not have an impact on local or distant tumour recurrence. Head and Neck 2005;27:1028-34. (Pubitemid 41705579)
76. Locati LD, Perrone F, Losa M, et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol 2009;45:986-90.
77. Jeng YM, Lin CY, Hsu HC. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 2000;154:107-11.
78. Sorensen KB, Godballe C, de Stricker K, et al. Parotid carcinoma: expression of kit protein and epidermal growth factor receptor. J Oral Pathol Med 2006;35:286-91.
79. Holst VA, Marshall CE, Moskaluk CA, et al. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Modern Pathol 1999;12:956-60. (Pubitemid 29485269)
80. Tang Y, Liang X, Zheng M, et al. Expression of c-kit and Slug correlates with invasion and metastasis of salivary adenoid cystic carcinoma. Oral Oncol 2010;46:311-16.
81. Freier K, Flechtenmacher C, Walch A, et al. Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland. Oral Oncol 2005;41:934-9. (Pubitemid 41265953)
82. Vila L, Liu H, Al-Quran SZ, et al. Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Modern Pathol 2009;22:1296-302.
83. Penner CR, Folpe AL, Budnick SD. C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Modern Pathol 2002;15:687-91. (Pubitemid 34787302)
84. Epivatianos A, Poulopoulos A, Dimitrakopoulos I, et al. Application of alpha-smooth muscle actin and c-kit in the differential diagnosis of adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Oral Oncology 2007;43:67-76. (Pubitemid 46162250)
85. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009;16:748-54.
86. Vered M, Braunstein E, Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head & Neck 2002;24:632-6. (Pubitemid 34734357)
87. Vidal L, Tsao MS, Pond GR, et al. Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head & Neck 2009;31:1006-12.
88. Dahse R, Driemel O, Schwarz S, et al. KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas. Oral Oncol 2009;45:826-9.
89. Chen CH, Li BY, Wan JT, et al. Expression of epidermal growth factor in salivary adenoid cystic carcinoma. Proc Natl Sci Counc Repub China B 2001;25:90-6.
90. Chiang CP, Chen CH, Liu BY, et al. Expression of transforming growth factor-alpha in adenoid cystic carcinoma of the salivary gland. J Formos Med Assoc 2001;100:471-7. (Pubitemid 32894821)
91. Sequeiros-Santiago G, Garcia-Carracedo D, Fresno MF, et al. Oncogene amplification pattern in adenoid cystic carcinoma of the salivary glands. Oncol Rep 2009;21:1215-22.
92. Macarenco RS, Uphoff TS, Gilmer HF, et al. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Modern Pathol 2008;21:1168-75.
93. Dahse R, Driemel O, Schwarz S, et al. Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. Br J Cancer 2009;100:623-5.
94. Sugano S, Mukai K, Tsuda H, et al. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope 1992;102:923-7.
95. Rosa JC, Felix A, Fonseca I, et al. Immunoexpression of c-erbB-2 and p53 in benign and malignant salivary neoplasms with myoepithelial differentiation. J Clin Pathol 1997;50:661-3. (Pubitemid 27396068)
96. Dori S, Vered M, David R, et al. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. J Oral Pathol Med 2002;31:463-7.
97. Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 2004;10:944-6. (Pubitemid 38198894)
98. Cho KJ, Lee SS, Lee YS. Proliferating cell nuclear antigen and c-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands. Head & Neck 1999;21:414-19.
99. Gan HK, Seruga B, Knox JJ. Sunitinib in solid tumors. Expert Opin Investig Drugs 2009;18:821-34.
100. Longo R, Gasparini G. Anti-VEGF therapy: the search for clinical biomarkers. Expert Rev Mol Diagn 2008;8:301-14. (Pubitemid 351724709)
101. Choi S, Sano D, Cheung M, et al. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model. [Erratum appears in Clin Cancer Res. 2009 Jan 1;15(1):416]. Clin Cancer Res 2008;14:5081-9.
102. Persson M, Andren Y, Mark J, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 2009;106:18740-4.
103. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004. (Pubitemid 36302244)
104. Faivre S, Raymond E, Casiraghi O, et al. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 2005;23:6271-3. author reply 6273-4.
105. Ratain MJ. Bar the windows but open the door to randomization. J Clin Oncol 2010;28:3104-6.